Pegylated interferon alpha-associated optic neuropathy
- PMID: 20351572
- PMCID: PMC3752854
- DOI: 10.1097/WNO.0b013e3181d8e4af
Pegylated interferon alpha-associated optic neuropathy
Abstract
A 52-year-old man with chronic hepatitis C presented with painless, bilateral, simultaneous nonarteritic anterior ischemic optic neuropathy (NAION) and peripheral neuropathy. Symptoms began 19 weeks after starting peginterferon alpha-2a. The peripheral neuropathy and vision of the right eye improved, but the vision of the left eye worsened after stopping interferon. We identified 23 additional cases of NAION during interferon alpha therapy. At least 12 of these patients suffered bilateral NAION. Patients lost vision 1-40 weeks after initiating therapy. Of 21 eyes that had documented initial and follow-up acuities, 8 improved, 1 worsened, and the rest remained stable. One patient had a painful peripheral neuropathy. Treatment with interferon alpha may result in NAION. Discontinuation of therapy deserves consideration after weighing individual risks and benefits.
Conflict of interest statement
None of the authors have any financial/conflicting interests to disclose. The sponsor or funding organization had no role in the design or conduct of this research.
Figures



Similar articles
-
Combined etiology for bilateral and simultaneous optic neuropathy in a patient with ciancobalamin deficit and hepatitis C treated with peg-interferon and ribavirin.Rom J Ophthalmol. 2016 Jul-Sep;60(3):188-194. Rom J Ophthalmol. 2016. PMID: 29450347 Free PMC article.
-
[Bilateral non-arteritic ischemic optic neuropathy during treatment of viral hepatitis C with pegylated interferon and Ribavirin].J Fr Ophtalmol. 2015 Jan;38(1):34-40. doi: 10.1016/j.jfo.2014.06.008. Epub 2014 Dec 18. J Fr Ophtalmol. 2015. PMID: 25533994 Review. French.
-
Anterior ischemic optic neuropathy in a patient with hepatitis C treated with interferon-alpha and ribavirin.Isr Med Assoc J. 2011 Apr;13(4):251-3. Isr Med Assoc J. 2011. PMID: 21598818 No abstract available.
-
[Peripheral polyneuropathy and bilateral optic neuropathy during treatment of chronic hepatitis C].Dtsch Med Wochenschr. 2009 Apr;134(18):927-30. doi: 10.1055/s-0029-1220250. Epub 2009 Apr 21. Dtsch Med Wochenschr. 2009. PMID: 19384811 German.
-
[Serious loss of vision in bilateral anterior ischemic optic neuropathy caused by interferon].Nippon Ganka Gakkai Zasshi. 2009 Jan;113(1):16-23. Nippon Ganka Gakkai Zasshi. 2009. PMID: 19227928 Review. Japanese.
Cited by
-
Bilateral retrobulbar optic neuropathy in the setting of interferon alpha-2a therapy.Case Rep Ophthalmol. 2014 Aug 27;5(2):270-6. doi: 10.1159/000366407. eCollection 2014 May. Case Rep Ophthalmol. 2014. PMID: 25298771 Free PMC article.
-
Combined etiology for bilateral and simultaneous optic neuropathy in a patient with ciancobalamin deficit and hepatitis C treated with peg-interferon and ribavirin.Rom J Ophthalmol. 2016 Jul-Sep;60(3):188-194. Rom J Ophthalmol. 2016. PMID: 29450347 Free PMC article.
-
A case of non-arteritic anterior ischemic optic neuropathy after completion of Harvoni therapy.Am J Ophthalmol Case Rep. 2017 Mar 8;6:55-57. doi: 10.1016/j.ajoc.2017.03.002. eCollection 2017 Jun. Am J Ophthalmol Case Rep. 2017. PMID: 29260058 Free PMC article.
-
Nonarteritic anterior ischemic optic neuropathy associated with interferon and ribavirin in a patient with hepatitis C.Am J Ophthalmol Case Rep. 2016 Dec 5;5:52-55. doi: 10.1016/j.ajoc.2016.12.004. eCollection 2017 Apr. Am J Ophthalmol Case Rep. 2016. PMID: 29503948 Free PMC article.
-
Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations.Graefes Arch Clin Exp Ophthalmol. 2019 Mar;257(3):447-452. doi: 10.1007/s00417-018-04209-7. Epub 2018 Dec 13. Graefes Arch Clin Exp Ophthalmol. 2019. PMID: 30547319 Review.
References
-
- Baron S, Tyring SK, Fleischmann WR, Jr, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ, Hughes TK. The interferons. Mechanisms of action and clinical applications. JAMA. 1991;266:1375–1383. - PubMed
-
- Bailon P, Palleroni A, Schaffer CA, Spence CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem. 2001;12:195–202. - PubMed
-
- Berenguer J, Gonzalez-Garcia J, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, Sanz J, Tural C, Ortega E, Mallolas J, Santos I, Miralles P, Montes ML, Bellon JM, Esteban JH GESIDA HIV/HCV Cohort. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother. 2009;63:1256–1263. - PubMed
-
- McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Bacon BR, Davis MN, Mukhopadhyay P, Kuory K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593. - PubMed
-
- Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25:283–291. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical